Report top-line data from Cohort A of the HOPE-3 trial

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 14 Nov 2023
Due: 31 Dec 2024
Checked: 1 Oct 2026

Deadline
Met
Late
Not met
Today

What the company said

“Plan to report top-line data from Cohort A in the fourth quarter of 2024.”

SourceCapricor Therapeutics, Inc. Form 8-K press release, 2023-11-14
FilingSEC filing index
Deadline as statedfourth quarter of 2024
Deadline used31 Dec 2024, the last day of the stated period
TypeProject
Permanent referenceKI-C-2023-CAPR-002538
Cite as https://keptindex.org/c/KI-C-2023-CAPR-002538/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company did not report top-line data from Cohort A of the HOPE-3 trial by the fourth quarter of 2024, with later filings indicating the data was expected in late 2025.

A
Capricor Therapeutics, Inc. 10-Q filed 2025-11-10 Regulatory filing · published 10 Nov 2025 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint f4ba9fa17cf4
“Topline HOPE-3 data are expected in the coming weeks (fourth quarter of 2025)” ✓ confirmed on the page

Market reaction: the shares moved -2.9% against the S&P 500 over the three sessions around the disclosure (7 Nov 2025 to 12 Nov 2025). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Language weakened: expected → aspirational
2 versions

Version 1 · original · stated 14 Nov 2023

Deadline 31 Dec 2024 (“fourth quarter of 2024”) · wording expected
Version 2 · stated 29 Feb 2024

Deadline 31 Dec 2024 (“in the fourth quarter of 2024”) · wording aspirational

“Plan to report topline data from HOPE-3 (Cohort A) in the fourth quarter of 2024”
Source for this version
Version 3 · stated 13 May 2024

Deadline 31 Dec 2024 (“Q4 2024”) · wording firm

“On Track to Report Top-Line Data in Q4 2024”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: Top-line data from Cohort A
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.